Table 1 The clinical characteristics of the men included in the study who were initially considered for curative treatment, categorized by whether choline PET/CT was performed or not
No PET/CT | PET/CT | |
|---|---|---|
n = 104 | n = 213 | |
Age, yrs | ||
Mean (SD) | 67.6 (4.9) | 68.3 (5.5) |
PSA, ng/ml | ||
Median (IQR) | 9.3 (6.1–22) | 20 (8.6–37) |
Gleason Score, n (%) | ||
3 + 3 | 2 (2) | 8 (4) |
3 + 4 | 14 (14) | 29 (14) |
4 + 3 | 7 (7) | 29 (14) |
4 + 4/3 + 5/5 + 3 | 43 (41) | 49 (23) |
4 + 5/5 + 4/5 + 5 | 38 (37) | 98 (46) |
Clinical tumor stage, n (%) | ||
TX | 1 (1) | |
T1 | 39 (38) | 60 (28) |
T2 | 37 (36) | 79 (37) |
T3 | 25 (24) | 72 (34) |
T4 | 2 (2) | 2 (1) |
Proportion of positive biopsy cores, % | ||
Median (IQR) | 50 (20–67) | 64 (40–92) |
No. high-risk criteria, n (%) | ||
1 | 80 (77) | 119 (56) |
2 | 15 (14) | 69 (32) |
3 | 9 (9) | 25 (12) |
Probability of N1a, % | ||
Median (IQR) | 5 (5–35) | 35 (15–65) |
Primary treatment given after all evaluations, n (%) | ||
None | 3 (3) | 1 (1) |
ADT | 18 (17) | 40 (19) |
RP | 66 (64) | 67 (32) |
RT | 17 (16) | 105 (49) |